在肺移植后同时服用塔克罗利斯时,埃莱克萨卡夫托尔-特萨卡夫托尔-伊瓦卡夫托尔的药理动力学
J S Guimbellot1, Ashritha Chalamalla2, Elizabeth Baker3
1Department of Pediatrics, Section of Pulmonary and Sleep Medicine, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR, USA.
患有囊性纤维化肺移植的接受者中的elexacaftor/tezacaftor/ivacaftor (ETI) 度与非移植个体中的度相似. 这表明ETI对于接受塔克罗利斯的移植患者来说是安全有效的.
科学领域:
- 药理动力学 药理动力学
- 囊性纤维化 囊性纤维化
- 肺部移植 肺部移植
背景情况:
- 由于安全问题,像ETI这样的CFTR调节器在肺移植接受者中未得到充分利用.
- 对于影响移植结果的CF并发症,ETI提供了好处.
- 在肺移植接受者中使用ETI是不一致的.
研究的目的:
- 评估ETI及其代谢物在接受肺移植患者中的药理动力学.
- 为了比较TAI度的肺移植接受者在TACROLIMUS与非移植的囊性纤维化患者.
主要方法:
- 一项前性观察性研究比较了12名接受塔克罗利斯肺移植的肺部移植患者和14名非移植性囊性纤维化患者的ETI药理动力学.
- 使用非分组分析分析了包括AUC和Cavg在内的药理动力学参数.
- 服用相互作用药物的参与者被排除在外.
主要成果:
- 移植和非移植组之间在ETI母化合物或代谢物的药理学参数中没有发现显著差异.
- 在治疗范围之外的度的频率在两组中都是相似的.
- 同时服用塔克罗利斯似乎不会改变ETI的药理动力学.
结论:
- 肺部移植接受者和非移植的患有囊性纤维化的人之间,ETI度是可比的.
- 这些发现支持ETI在肺移植接受者的安全使用.
- 进一步的研究可能会探索长期结果和最佳剂量.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
11:49Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
相关概念视频
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
